# A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

> **NCT01227889** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 251 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK2118436
- **DRUG:** Dacarbazine (DTIC)

## Key facts

- **NCT ID:** NCT01227889
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-23
- **Primary completion:** 2011-12-19
- **Final completion:** 2016-09-16
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2017-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227889, "A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01227889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*